Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
Phase 1
Completed
- Conditions
- Adenocarcinoma
- Registration Number
- NCT00051675
- Lead Sponsor
- XOMA (US) LLC
- Brief Summary
The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does ING-1(heMAb) target in advanced adenocarcinomas?
How does subcutaneous monoclonal antibody administration compare to standard intravenous therapies in phase I cancer trials?
Are there specific biomarkers associated with response to human-engineered monoclonal antibodies like ING-1(heMAb) in refractory adenocarcinomas?
What adverse events are commonly reported in phase I trials of subcutaneously administered monoclonal antibodies for advanced cancers?
What other monoclonal antibodies or combination therapies are being developed by XOMA (US) LLC for treatment-resistant adenocarcinomas?
Trial Locations
- Locations (1)
Jack D. Weiler Hospital of the Albert Einstein College of Medicine
🇺🇸Bronx, New York, United States
Jack D. Weiler Hospital of the Albert Einstein College of Medicine🇺🇸Bronx, New York, United States